StockNews.com upgraded shares of Anika Therapeutics (NASDAQ:ANIK – Free Report) from a hold rating to a buy rating in a report issued on Thursday morning.
Separately, Barrington Research lowered their price objective on shares of Anika Therapeutics from $25.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday.
Check Out Our Latest Stock Report on ANIK
Anika Therapeutics Stock Up 4.6 %
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The business had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. As a group, equities research analysts anticipate that Anika Therapeutics will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On Anika Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mackenzie Financial Corp bought a new stake in Anika Therapeutics during the 4th quarter worth approximately $231,000. Public Employees Retirement System of Ohio bought a new stake in Anika Therapeutics during the 4th quarter worth approximately $137,000. Squarepoint Ops LLC bought a new stake in Anika Therapeutics during the 4th quarter worth approximately $212,000. Stonepine Capital Management LLC raised its stake in Anika Therapeutics by 25.8% during the 4th quarter. Stonepine Capital Management LLC now owns 238,222 shares of the biotechnology company’s stock worth $3,921,000 after acquiring an additional 48,914 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Anika Therapeutics during the 4th quarter worth approximately $1,958,000. Institutional investors own 91.53% of the company’s stock.
About Anika Therapeutics
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Featured Articles
- Five stocks we like better than Anika Therapeutics
- How to Calculate Options Profits
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to trade using analyst ratings
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Dogs of the Dow Strategy? Overview and Examples
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.